Most quarters, a hedge fund’s 13F filing doesn’t tell you much about conviction. It tells you what a fund owned on one specific day, nothing about why.
Armistice Capital’s position in Bicycle Therapeutics is one of the rare cases where the timing itself says something, because the fund built up its stake right before the company’s most advanced drug hit a wall, and then didn’t sell.
Buying In Before the Setback
Armistice added 258,000 shares of Bicycle Therapeutics in the fourth quarter of 2025, bringing its total to 3,236,000 shares at an average price of $7.08, according to a filing summary. That stake gave Armistice 6.48% ownership of the British drug developer, though it amounted to just 0.34% of the fund’s reported portfolio. Bicycle Therapeutics builds what it calls Bicycle molecules, small, constrained peptides designed to hit cancer targets that antibodies and small-molecule drugs struggle to reach.
The company’s lead program at the time was zelenectide pevedotin, a treatment for metastatic urothelial cancer moving through the Phase 2/3 Duravelo-2 trial in combination with the immunotherapy pembrolizumab. Bicycle was waiting on something specific: meetings with the Food and Drug Administration, the European Medicines Agency and U.K. regulators to help decide whether to push the drug toward a full registrational filing, London Loves Business reported. Chief Executive Kevin Lee had described the goal plainly: the company was “seeking broad regulatory feedback to make an informed decision on our path forward with zelenectide pevedotin in metastatic urothelial cancer.”
The Feedback Arrives, and the Plan Changes
By the time Bicycle reported its first-quarter 2026 results, the regulatory meetings had happened, and the answer wasn’t a green light to keep racing toward approval. The company converted Duravelo-2 from a registrational trial into a randomized Phase 2 study and pulled back on developing zelenectide pevedotin internally, redirecting resources toward earlier-stage programs instead, the company’s own quarterly release stated. Lee framed it this way: “Following a strategic reprioritization in the first quarter, we are converting the Duravelo-2 trial into a randomized Phase 2 trial, allowing us to focus our internal resources on our emerging pipeline of next-generation therapeutics, including nuzefatide and Bicycle-based radiotherapeutics and imaging agents.”
None of this reflected a failed drug. Duravelo-2 had already shown real activity: a physician-assessed overall response rate of 65% at the 27-week mark, with an independent blinded review confirming 58%, later revised to 62%, and only one patient discontinuing treatment because of side effects. What changed wasn’t the data so much as the company’s appetite to fund a costly Phase 3 push on its own. Bicycle cut its research and development spending to $48.9 million in the first quarter, down from $59.1 million a year earlier, alongside workforce reductions the company announced that March, and stretched its cash runway into 2030 in the process.
The stock had already priced in some of that caution. Shares traded around $5.65 by late February 2026, down more than 20% from where Armistice had bought in three months earlier, even as one valuation model pegged the stock’s intrinsic worth closer to $11.89, GuruFocus data showed at the time.
Holding Steady Through the Second Quarter
Armistice’s response to all of this was to do nothing, at least on paper. A Schedule 13G/A filed in May 2026 showed the fund still holding 3,398,000 American depositary shares, 6.75% of the class, a filing record shows. A second amendment filed that August, reporting the position as of June 30, put the stake at 6.72%, the same share count with a slightly diluted percentage.
Armistice Capital‘s 13F for the same quarter confirmed it: 3.4 million shares, worth about $14 million, 0.2% of the fund’s total reported portfolio, with no change in share count from the prior quarter, fund-tracking data compiled by StockZoa show. Three separate filings, two 13G amendments and one 13F, all landed on the identical share count for the quarter, which is its own small piece of evidence: nobody at Armistice was trading in and out of Bicycle Therapeutics between reporting periods. The position simply sat.
By the second quarter, Bicycle Therapeutics had more to point to than the deprioritized trial. Cash and equivalents stood at $510.1 million as of June 30, down from $628.1 million at the end of 2025 but still enough, the company said, to fund operations into 2030. The net loss narrowed to $50.3 million from $79.0 million a year earlier, and research and development spending fell further, to $41.2 million from $71.0 million, the company reported in its second-quarter results. Zelenectide pevedotin itself kept generating usable data even in its reduced role: the converted Duravelo-2 study reported a 62% confirmed overall response rate in previously untreated patients, with no severe skin reactions and what the company called a differentiated safety profile.
The newer programs Lee had pointed to were moving, too. Nuzefatide, targeting the EphA2 receptor, dosed its first patient in a Phase 2 pancreatic cancer trial that April, backed by preclinical work showing sensitivity in 10 of 14 pancreatic cancer models tested. A separate imaging agent aimed at the same target showed it could translate to human patients in a small study of seven people with pancreatic cancer, and the company said a Phase 1 trial of a radioconjugate called BT1702 should begin in 2027. Lee summarized the quarter by saying Bicycle was “well capitalized to pursue our mission to help patients to not only live longer, but also live well.”
What a Flat Filing Actually Shows
Armistice Capital, founded by Steven Boyd in 2012, describes itself as a global, long/short, value-oriented and event-driven fund built around healthcare and consumer investments. Bicycle Therapeutics fits the healthcare half of that mandate in a way that doesn’t map neatly onto Armistice’s more familiar playbook of concentrated bets tied to a single binary catalyst.
Here, the catalyst came and went. The company’s answer to its own regulatory feedback was to shrink the bet on its lead drug rather than walk away from it entirely, and Armistice’s own bet moved in exactly the same direction: not larger, not smaller, just held.
Armistice isn’t the biggest name on Bicycle Therapeutics’ shareholder list, and it isn’t close. Baker Bros. Advisors, a hedge fund built almost entirely around biotech and pharmaceutical stakes, held a far larger position, one large enough that the two funds together with a third holder, Forbion Capital Partners, controlled a majority of the company’s stock, Yahoo Finance reported in a 2025 ownership breakdown. That kind of concentration is common among small biotechs whose fortunes hinge on one or two clinical programs. When Baker Bros. or a similarly sized holder decides whether to keep backing a company through a strategic reset, that decision carries far more weight than anything a smaller position like Armistice’s can signal on its own.
A fund that owns 6.72% of a company’s shares outstanding, yet counts that position as two-tenths of one percent of its own book, isn’t making a claim about Bicycle Therapeutics being central to its returns. What the position does show is a fund willing to sit through a strategic reset rather than treat a deprioritized trial as a reason to exit, a pattern that shows up across long/short and value-oriented portfolios more often than headlines about drug setbacks might suggest. Every filing on Bicycle Therapeutics, like every other position Armistice reports, comes from the same Madison Avenue address, a business listing for Armistice Capital South LLC shows, filed on the same quarterly rhythm that will eventually say whether the fund kept its patience into 2027.
